LanthaScreen™ fluorescent coregulator peptides for nuclear receptors contain known interaction motifs and are labeled with fluorescein.

Contact us for quote

Peptide 100 μl Sequence Description
SRC1-1 PV4576 KYSQTSHKLV-
QLLTTTAEQQL
Peptide contains the nuclear receptor box1 (LXXLL motif) of SRC-1, member of the p160 coactivator steroid receptor coactivators.1
SRC1-2 PV4578 LTARHKILHR-
LLQEGSPSD
Peptide contains the nuclear receptor box2 (LXXLL motif) of SRC-1, member of the p160 coactivator steroid receptor coactivators.1
SRC1-3 PV4580 ESKDHQLLR-
YLLDKDEKDL
Peptide contains the nuclear receptor box3 (LXXLL motif) of SRC-1, member of the p160 coactivator steroid receptor coactivators.1
SRC1-4 PV4582 GPQTPQAQQ-
KSLLQQLLTE
Peptide contains the nuclear receptor box4 (LXXLL motif) of SRC-1, member of the p160 coactivator steroid receptor coactivators.1
SRC2-1 PV4584 DSKGQTKLLQ-
LLTTKSDQM
Peptide contains the nuclear receptor box1 (LXXLL motif) of SRC-2, member of the p160 coactivator steroid receptor coactivators.2
SRC2-2 PV4586 LKEKHKILHRLL-
QDSSSPV
Peptide contains the nuclear receptor box2 (LXXLL motif) of SRC-2, member of the p160 coactivator steroid receptor coactivators.2
SRC2-3 PV4588 KKKENALLRYLL-
DKDDTKD
Peptide contains the nuclear receptor box3 (LXXLL motif) of SRC-2, member of the p160 coactivator steroid receptor coactivators.2
SRC3-1 PV4590 ESKGHKKLLQ-
LLTCSSDDR
Peptide contains the nuclear receptor box1 (LXXLL motif) of SRC-3, member of the p160 coactivator steroid receptor coactivators.3
SRC3-2 PV4592 LQEKHRILHK-
LLQNGNSPA
Peptide contains the nuclear receptor box2 (LXXLL motif) of SRC-3, member of the p160 coactivator steroid receptor coactivators.3
SRC3-3 PV4594 KKENNALLRY-
LLDRDDPSD
Peptide contains the nuclear receptor box3 (LXXLL motif) of SRC-3, member of the p160 coactivator steroid receptor coactivators.3
CBP-1 PV4596 AASKHKQLSE-
LLRGGSGSS
This peptide contains the LXXLL motif 1 of CREB binding protein and is involved in ligand-dependent nuclear receptor interactions.4
TRAP220/DRIP-1 PV4598 KVSQNPILT-
SLLQITGNGG
This peptide is the LXXLL motif 1 of the VDR-interacting proteins which interact in a ligand-dependent manner with nuclear receptors.5
TRAP220/DRIP-2 PV4549 NTKNHPML-
MNLLKDNPAQD
This peptide is the LXXLL motif 2 of the VDR-interacting proteins which interact in a ligand-dependent manner with nuclear receptors.5
RIP140 L6 PV4600 SHQKVTLLQ-
LLLGHKNEEN
This peptide is derived from the Nuclear receptor interacting protein 1, LxxLL motif 6, known to interact in a ligand-dependent manner with the activation domains of nuclear receptors.6
RIP140 L8 PV4602 SFSKNGLLS-
RLLRQNQDSY
This peptide is derived from the Nuclear receptor interacting protein 1, LxxLL motif 8, known to interact in a ligand-dependent manner with the activation domains of nuclear receptors.6
PGC1a PV4421 EAEEPSLLK-
KLLLAPANTQ
This peptide is derived from the PPARg coactivator protein 1a and contains an LXXLL motif.7
PRIP/RAP250 PV4604 VTLTSPLLVNL-
LQSDISAG
This peptide contains the LXXLL-interaction motif of the PPAR interacting protein, PRIP.4
D22 PV4386 LPYEGSLLLK-
LLRAPVEEV
Peptide was discovered from random phage display and contains sequences that resemble the known coregulatory proteins, RIP140, PCG-1, DAX-1, and SHP.8
C33 PV4606 HVEMHPLLMG-
LLMESQWGA
Peptide was discovered from random phage display and contains sequences that resemble the known coregulatory proteins, TRAP220 and RIP140.8
EAB1 PV4608 SSNHQSSR-
LIELLSR
Peptide was discovered from random phage display to find tamoxifen-induced interactions with ER.9
EA2 PV4610 SSKGVLWRM-
LAEPVSR
Peptide was discovered from random phage display to find tamoxifen-induced interactions with ER.10
TB3 PV4614 SSVASREW-
WVRELSR
Peptide was discovered by random phage display during tamoxifen-induced interactions with ER.10
AR(16-34) PV4616 SKTYRGAFQ-
NLFQSVREVI
This peptide is the N-terminal sequence of AR which mediates a ligand-induced intradomain interaction with the ligand binding domain.11
ARA70 PV4618 SRETSEKFKL-
LFQSYNVND
This peptide is the FxxLF motif of the AR-specific coactivator, ARA70.11
D11 FxxLF PV4382 VESGSSRFM-
QLFMANDLLT
This random phage display peptide had been modified to contain the AR-specific FxxLF interaction motif.11
SMRT ID1 PV4620 GHQRVVTLA-
QHISEVITQDYTRH
This peptide contains the interaction motif 1 of the corepressor protein, Silencing Mediator for Retinoid and Thyroid-hormone receptors.12
SMRT ID2 PV4423 HASTNMGLEA-
IIRKALMGKYDQW
This peptide contains the interaction motif 1 of the corepressor protein, Silencing Mediator for Retinoid and Thyroid-hormone receptors.12
NCoR ID1 PV4622 RTHLITLADH-
ICQIITQDFARN
This peptide contains motif 1 of the Nuclear CoRepressor protein.13
NCoR ID2 PV4624 DPASNLGLEDII-
RKALMGSFDDK
This peptide contains motif 2 of the Nuclear CoRepressor protein.13

References

  • Onate SA, Tsai SY, Tsai MJ, O’Malley BW (1995) Science 270:1354-1357
  • Takeshita A, Yen PM, Misiti S, Cardona GR, Liu Y, Chin WW (1996) Endocrinology 137: 3594-3597.
  • Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS (1997) Science 277:965-968.
  • Caira F, Antonson P, Pelto-Huikko M, Treuter E, Gustafsson J-A (2000) J Biol Chem 275:5308-5317.
  • Rachez C, Gamble M, Chang C-PB, Atkins GB, Lazar MA, Freedman LP (2000) Mol Cell Biol 20:2718-2726.
  • Cavailles V, Dauvois S, L’Horset F, Lopez F, Hoare S, Kushner PJ, Parker MG (1995) EMBO J. 14:3741-3751.
  • Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM (1998) Cell 92: 829-839
  • Chang CY, Norris JD, Grøn H, Paige LA, Hamilton PT, Kenan DJ, Fowlkes D, McDonnell DP (1999) Mol Cell Biol 19:8226-8239.
  • Norris JD, Paige LA, Christensen DJ, Chang CY, Huacani MR, Fan D, Hamilton PT, Fowlkes DM, McDonnell DP (1999) Science 285:744-746.
  • Heldring N, Nilsson M, Buehrer B, Trueter E, Gustafsson J-A (2004) Mol Cell Biol 24:3445-3459.
  • He B, Minges JT, Lee LW, Wilson EM (2002) J Biol Chem 277:10226-10235.
  • Chen JD, Evans RM (1995) Nature 377:454-457.
  • Perissi V, Staszewski LM, McInerney EM, Kurokawa R, Krones A, Rose DW, Lambert MH, Milburn MV, Glass CK, Rosenfeld MG (1999) Genes Dev 13:3198-3208.
Peptide 100 μl Sequence Description
SRC1-1 PV4576 KYSQTSHKLV-
QLLTTTAEQQL
Peptide contains the nuclear receptor box1 (LXXLL motif) of SRC-1, member of the p160 coactivator steroid receptor coactivators.1
SRC1-2 PV4578 LTARHKILHR-
LLQEGSPSD
Peptide contains the nuclear receptor box2 (LXXLL motif) of SRC-1, member of the p160 coactivator steroid receptor coactivators.1
SRC1-3 PV4580 ESKDHQLLR-
YLLDKDEKDL
Peptide contains the nuclear receptor box3 (LXXLL motif) of SRC-1, member of the p160 coactivator steroid receptor coactivators.1
SRC1-4 PV4582 GPQTPQAQQ-
KSLLQQLLTE
Peptide contains the nuclear receptor box4 (LXXLL motif) of SRC-1, member of the p160 coactivator steroid receptor coactivators.1
SRC2-1 PV4584 DSKGQTKLLQ-
LLTTKSDQM
Peptide contains the nuclear receptor box1 (LXXLL motif) of SRC-2, member of the p160 coactivator steroid receptor coactivators.2
SRC2-2 PV4586 LKEKHKILHRLL-
QDSSSPV
Peptide contains the nuclear receptor box2 (LXXLL motif) of SRC-2, member of the p160 coactivator steroid receptor coactivators.2
SRC2-3 PV4588 KKKENALLRYLL-
DKDDTKD
Peptide contains the nuclear receptor box3 (LXXLL motif) of SRC-2, member of the p160 coactivator steroid receptor coactivators.2
SRC3-1 PV4590 ESKGHKKLLQ-
LLTCSSDDR
Peptide contains the nuclear receptor box1 (LXXLL motif) of SRC-3, member of the p160 coactivator steroid receptor coactivators.3
SRC3-2 PV4592 LQEKHRILHK-
LLQNGNSPA
Peptide contains the nuclear receptor box2 (LXXLL motif) of SRC-3, member of the p160 coactivator steroid receptor coactivators.3
SRC3-3 PV4594 KKENNALLRY-
LLDRDDPSD
Peptide contains the nuclear receptor box3 (LXXLL motif) of SRC-3, member of the p160 coactivator steroid receptor coactivators.3
CBP-1 PV4596 AASKHKQLSE-
LLRGGSGSS
This peptide contains the LXXLL motif 1 of CREB binding protein and is involved in ligand-dependent nuclear receptor interactions.4
TRAP220/DRIP-1 PV4598 KVSQNPILT-
SLLQITGNGG
This peptide is the LXXLL motif 1 of the VDR-interacting proteins which interact in a ligand-dependent manner with nuclear receptors.5
TRAP220/DRIP-2 PV4549 NTKNHPML-
MNLLKDNPAQD
This peptide is the LXXLL motif 2 of the VDR-interacting proteins which interact in a ligand-dependent manner with nuclear receptors.5
RIP140 L6 PV4600 SHQKVTLLQ-
LLLGHKNEEN
This peptide is derived from the Nuclear receptor interacting protein 1, LxxLL motif 6, known to interact in a ligand-dependent manner with the activation domains of nuclear receptors.6
RIP140 L8 PV4602 SFSKNGLLS-
RLLRQNQDSY
This peptide is derived from the Nuclear receptor interacting protein 1, LxxLL motif 8, known to interact in a ligand-dependent manner with the activation domains of nuclear receptors.6
PGC1a PV4421 EAEEPSLLK-
KLLLAPANTQ
This peptide is derived from the PPARg coactivator protein 1a and contains an LXXLL motif.7
PRIP/RAP250 PV4604 VTLTSPLLVNL-
LQSDISAG
This peptide contains the LXXLL-interaction motif of the PPAR interacting protein, PRIP.4
D22 PV4386 LPYEGSLLLK-
LLRAPVEEV
Peptide was discovered from random phage display and contains sequences that resemble the known coregulatory proteins, RIP140, PCG-1, DAX-1, and SHP.8
C33 PV4606 HVEMHPLLMG-
LLMESQWGA
Peptide was discovered from random phage display and contains sequences that resemble the known coregulatory proteins, TRAP220 and RIP140.8
EAB1 PV4608 SSNHQSSR-
LIELLSR
Peptide was discovered from random phage display to find tamoxifen-induced interactions with ER.9
EA2 PV4610 SSKGVLWRM-
LAEPVSR
Peptide was discovered from random phage display to find tamoxifen-induced interactions with ER.10
TB3 PV4614 SSVASREW-
WVRELSR
Peptide was discovered by random phage display during tamoxifen-induced interactions with ER.10
AR(16-34) PV4616 SKTYRGAFQ-
NLFQSVREVI
This peptide is the N-terminal sequence of AR which mediates a ligand-induced intradomain interaction with the ligand binding domain.11
ARA70 PV4618 SRETSEKFKL-
LFQSYNVND
This peptide is the FxxLF motif of the AR-specific coactivator, ARA70.11
D11 FxxLF PV4382 VESGSSRFM-
QLFMANDLLT
This random phage display peptide had been modified to contain the AR-specific FxxLF interaction motif.11
SMRT ID1 PV4620 GHQRVVTLA-
QHISEVITQDYTRH
This peptide contains the interaction motif 1 of the corepressor protein, Silencing Mediator for Retinoid and Thyroid-hormone receptors.12
SMRT ID2 PV4423 HASTNMGLEA-
IIRKALMGKYDQW
This peptide contains the interaction motif 1 of the corepressor protein, Silencing Mediator for Retinoid and Thyroid-hormone receptors.12
NCoR ID1 PV4622 RTHLITLADH-
ICQIITQDFARN
This peptide contains motif 1 of the Nuclear CoRepressor protein.13
NCoR ID2 PV4624 DPASNLGLEDII-
RKALMGSFDDK
This peptide contains motif 2 of the Nuclear CoRepressor protein.13

References

  • Onate SA, Tsai SY, Tsai MJ, O’Malley BW (1995) Science 270:1354-1357
  • Takeshita A, Yen PM, Misiti S, Cardona GR, Liu Y, Chin WW (1996) Endocrinology 137: 3594-3597.
  • Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS (1997) Science 277:965-968.
  • Caira F, Antonson P, Pelto-Huikko M, Treuter E, Gustafsson J-A (2000) J Biol Chem 275:5308-5317.
  • Rachez C, Gamble M, Chang C-PB, Atkins GB, Lazar MA, Freedman LP (2000) Mol Cell Biol 20:2718-2726.
  • Cavailles V, Dauvois S, L’Horset F, Lopez F, Hoare S, Kushner PJ, Parker MG (1995) EMBO J. 14:3741-3751.
  • Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM (1998) Cell 92: 829-839
  • Chang CY, Norris JD, Grøn H, Paige LA, Hamilton PT, Kenan DJ, Fowlkes D, McDonnell DP (1999) Mol Cell Biol 19:8226-8239.
  • Norris JD, Paige LA, Christensen DJ, Chang CY, Huacani MR, Fan D, Hamilton PT, Fowlkes DM, McDonnell DP (1999) Science 285:744-746.
  • Heldring N, Nilsson M, Buehrer B, Trueter E, Gustafsson J-A (2004) Mol Cell Biol 24:3445-3459.
  • He B, Minges JT, Lee LW, Wilson EM (2002) J Biol Chem 277:10226-10235.
  • Chen JD, Evans RM (1995) Nature 377:454-457.
  • Perissi V, Staszewski LM, McInerney EM, Kurokawa R, Krones A, Rose DW, Lambert MH, Milburn MV, Glass CK, Rosenfeld MG (1999) Genes Dev 13:3198-3208.

For research use only. Not intended for any animal or human therapeutic or diagnostic use.